Discontinued — last reported Q3 '18
Eli Lilly Available-for-Sale Debt Securities - Fair Value (Maturing Over 10 Years) decreased by 44.0% to $160.10M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 45.4%, from $293.40M to $160.10M.
afs_debt_securities_fair_value_over_10y| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $189.30M | $168.80M | $159.80M | $171.90M | $205.70M | $237.20M | $247.30M | $229.10M | $245.80M | $255.20M | $293.40M | $290.90M | $285.80M | $160.10M |
| QoQ Change | — | -10.8% | -5.3% | +7.6% | +19.7% | +15.3% | +4.3% | -7.4% | +7.3% | +3.8% | +15.0% | -0.9% | -1.8% | -44.0% |
| YoY Change | — | — | — | -9.2% | +21.9% | +48.4% | +43.9% | +11.4% | +3.6% | +3.2% | +28.1% | +18.3% | +12.0% | -45.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.